Share on LinkedInShare on LinkedIn

ARTICLE · 04 FEBRUARY 2016

Keep Taking The Tablets: Flynn Pharma v DrugsRUs

Wedlake Bell LLP
Wedlake Bell LLP
Contributor
Wedlake Bell LLP

Wedlake Bell LLP

Wedlake Bell provides clients with a full package of legal services delivering commercial and...

View firm profile
Explore more from Wedlake Bell LLP

Pfizer is a giant pharmaceutical manufacturer whose range of pharmaceuticals includes phenytoin sodium, an anti-epilepsy drug sold in the EU under the brand name EPANUTIN.

United KingdomIntellectual Property

This article summarises a recent trade mark judgment in the English High Court illustrating the legal problems that can arise when branded goods are traded and/or advertised across the internal borders of the European Union's single market.

The parties

Pfizer is a giant pharmaceutical manufacturer whose range of pharmaceuticals includes phenytoin sodium, an anti-epilepsy drug sold in the EU under the brand name EPANUTIN.  Flynn Pharma (the claimant), a UK pharmaceutical supplier, purchased from Pfizer the UK marketing authorisations to the product, which, for regulatory reasons, it then rebranded to PHENYTOIN SODIUM FLYNN (the Rebrand).  DrugsRUs, a British parallel importer, planned to purchase the product from EU sources and parallel-import it into the UK under and by reference to the Rebrand.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from